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Abstract 
Purpose: To investigate the efficacy of lentinan in relieving hepatitis B surface antigen (HBsAg)-
induced functional impairment of monocytes/macrophages.  
Methods: Monocytic cell line THP-1 was incubated with lentinan and HBsAg for 24 h and then 
stimulated with LPS (Lipopolysaccharide). The expression levels of interleukin-1β (IL-1β), IL-12 and 
tumour necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent (ELISA) assays 
and quantitative reverse transcriptase-PCR (q-PCR). Protein levels of IkB-α, phospho-ERK, and 
phospho-p38 were measured by western blotting. 
Results: THP-1 cells treated with lentinan and HBsAg showed higher IL-1β, IL-12, and TNF-α levels 
than cells treated with HBsAg alone. The underlying mechanisms were associated with NF-kB and 
MAPK signal pathways. Decreased expression of IkB-α and phospho-ERK and increased expression of 
phospho-JNK and phospho-p38 were observed in cells treated with lentinan and HBsAg when 
compared with cells treated with HBsAg alone (p < 0.001). THP-1 cells incubated with 500 μg/mL 
lentinan secreted lower levels of cytokines than did control cells after LPS stimulation, suggesting an 
anti-inflammatory effect for lentinan.  
Conclusion: Lentinan shows both pro- and anti-inflammatory functions and may be a promising 
candidate for hepatitis B virus (HBV) treatment. 
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Hepatitis B virus (HBV), a non-cytopathic DNA 
virus with a partially duplex circular genome of 
3.2 kb, infects more than 350 million people 
worldwide [1,2]. Chronic HBV infection is the 
main cause of hepatocellular carcinoma, which is 
prevalent in the Asian population [3]. Multiple 
immune-subversion strategies employed by HBV 
disrupt the host innate and adaptive immune 
responses and result in systemic immuno-
suppression [1,4]. Hepatitis B surface antigen 
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(HBsAg) is a leading cause of weak antiviral 
immune responses to HBV infection [5]. High 
levels of HBsAg are detected in peripheral blood 
and liver of patients chronically infected with HBV 
[6,7]. Therefore, an important concern with 
HBsAg is that HBsAg can directly repress the 
active progression of circulating and liver 
monocytes/macrophages [8,9]. HBsAg or HBV 
can inhibit the production of type I IFN and IL-12 
by antigen presenting cells in a Toll-like receptor 
(TLR)-dependent manner. Furthermore, the 
functional activity of monocyte/macrophage were 
strongly impaired by HBsAg through TLRs, 
suggesting that HBsAg serves as a suppresser 
to hamper host innate immune responses 
[10,11].  
 
Lentinan from shiitake mushrooms (Lentinula 
edodes) is a β-1,3 β-glucan with β-1,6 branching 
and a molecular weight of 500 kDa [12]. Since 
1985, lentinan has been approved as an 
adjuvant for stomach cancer in Japan due to its 
effects on host immune systems. Lentinan can 
enhance the functional activity of 
monocytes/macrophages and the anti-tumour 
activity of cytotoxic T lymphocytes (CTLs) 
[13,14]. However, the potential of lentinan to treat 
HBV infection remains unstudied.  
 
In this study, lentinan was used to relieve 
HBsAg-induced impairment of cytokine secretion 
by THP-1 cells. The NF-kB and MAPK signalling 
that was hampered by HBsAg was activated in 
the presence of lentinan. Lentinan also 
repressed cytokine production by THP-1 cells 
upon LPS stimulation. These data indicate that 







HBsAg was purified from the serum of HBV 
patients using sucrose gradient centrifugation 
and affinity chromatography. Lentinan was 
purchased from Kanghaipharm (Shanghai, 
China). Polyclonal anti–phospho (p)-ERK, anti-
ERK, and anti-IkB-α and monoclonal anti–
phospho-JNK, anti–JUK, anti–p-p38, and anti–
p38 were obtained from Cell Signaling 
Technology (Danvers, MA, USA). Horseradish 
peroxidise (HRP)-conjugated goat anti-
mouse/rabbit antibodies were obtained from 
Jackson Laboratory. 
 
Cells and culture conditions  
 
THP-1 (the human monocytic leukaemia cell line) 
cells were obtained from ATCC (Manassas, 
Virginia, USA) and cultured in complete RPMI 
1640 medium which contained additional 10 % 
FBS, 1 % penicillin (100 IU/ml), and 1 % 
streptomycin (100 mg/mL) (Life Technologies, 
USA) at 37 oC with 5 % CO2. To activate THP-1 
cells for further assays, 50 ng/ml PMA were first 
added into the culture media for 24 h. Then with 
various concentrations of lentinan (100, 250 and 
500 μg/mL), with or without 25 μg/mL HBsAg in 
fresh complete RPMI 1640 were used in the 
further culture for another 24 h. The cells were 
washed and stimulated with LPS (100 ng/mL) for 
15 min or 6 h in complete RPMI 1640 medium. 
 
Enzyme-linked immunosorbent assay (ELISA)  
 
After LPS stimulation for 6 h, secreted IL-1β, IL-
12, and TNF-α levels were measured by ELISA 
kits (R & D Systems, USA) under the guidance of 
the manufacturer’s introduction. Supernatants 
were added to pre-coated plates in triplicate 
wells and incubated at 37 oC. After washed, 
HRP-labelled antibodies were added for 2 h. 
Substrate was added to washed plates. 
Chromogenic reactions were stopped with 10 % 
H2SO4. Absorbances450 nm were measured and 
the absolute amount of IL-1β, IL-12, and TNF-α 
were calculated based on standard curves. 
 
Total RNA extraction and quantitative 
reverse-transcriptase-PCR (q-PCR) 
 
A TRizol reagent (Invitrogen, USA) was used to 
extract total RNA in THP-1 cells. Then cDNA was 
synthesized using M-MLV (Promega, USA) 
under the guidance of the manufacturer’s 
introduction. To assess the gene transcription 
levels, q-PCR was performed using an ABI Step 
One Plus Real-Time PCR System (Applied 
Biosystems, CA, USA) and an EzOmics SYBR 
qPCR kit (Vazyme Biotech Co., Ltd.) under the 
guidance of the manufacturer’s introduction. 
 
Western blot analysis 
 
THP-1 cells were treated with 100 ng/mL LPS for 
15 min. After two times of wash with ice-cold 
Phosphate Buffer solution (PBS), the cells were 
lysed in RIPA buffer containing 1 Mm 
phenylmethanesulfonyl fluoride and centrifuged. 
The supernatants were collected for protein 
quantification. Expression levels of IkB-α, p-p38, 
p-JNK, and p-ERK were analysed. The protein in 
samples were separated via 12 % SDS-PAGE 
and transferred to PVDF membranes. 
Membranes were gently rinsed in deionized 
water, blocked with skim milk, and incubated 12 
h with the antibodies indicated above (diluted 1 : 
1000 - 1 : 2000 in 1× PBS/0.05 % Tween 20) at 4 
℃. After washed, Membranes were incubated 
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with HRP-conjugated goat anti-rabbit/mouse 
antibodies for 2 h at room temperature. 





All data were analysed using SPSS 17.0 
statistical package and presented as mean ± 
standard deviation (SD). ANOVA or Student’s t-
tests were used to determine significance levels; 
p < 0.05 was considered significant. The data 





Lentinan relieves HBsAg-induced functional 
impairment of THP-1 cells 
 
To investigate if lentinan affects 
monocytes/macrophages treated with HBsAg, 
the protein concentrations of IL-1β, IL-12, and 
TNF-α in THP-1 culture supernatants were 
measured by ELISA (Figure 1 A-C). The results 
show that HBsAg repressed the expression of 
these cytokines at the mRNA and protein levels, 
indicating potent immuno-suppressive activity by 
lentinan (Figure 1 D-F). In the present of HBsAg, 
addition of lentinan significantly enhanced the 
production of IL-1β, IL-12, and TNF-α in a dose-
dependent manner. Interestingly, THP-1 cells 
incubated with 500 μg/mL lentinan alone showed 
a mild cytokine response to further stimulation 
with LPS, suggesting that lentinan induced a 
certain tolerance of THP-1 cells to LPS that 
coincided with the multiple functions of the 
polysaccharide. Thus, in response to further 
stimulation with LPS, lentinan relieved the 





Figure 1: Lentinan relieves HBsAg-induced functional 
impairment of THP-1 cells. 50 ng/mL PMA were used 
to stimulate THP-1 cell differentiation. Stimulated cells 
were incubated with HBsAg (25 μg/mL) and/or lentinan 
(100, 250, or 500 μg/mL) for 24 h. Cells were 
harvested and stimulated with LPS for another 6 h. 
Protein levels of IL-1β (A), IL-12 (B), and TNF-α (C) in 
culture supernatants were measured by ELISA. RNA 
was extracted from the cells. Relative IL-1β (D), IL-
12p40 (E), and TNF-α (F) mRNA levels were 
measured by q-PCR. Graph are presented as mean 
and SD. A significance level of p < 0.05, p < 0.01, and 
p < 0.001 were labelled with one to three asterisk 
respectively. (* vs. control; # vs. HBsAg; ^ vs. lentinan) 
 
Lentinan restores the function of HBsAg-
treated THP-1 cells by activating NF-kB 
signalling 
 
Lentinan and HBsAg alter the function of 
monocytes/macrophages though the NF-kB 
signalling pathway. Therefore, NF-kB signalling 
were examined in this cell culture model using 
western blotting analysis. The engagement of 
HBsAg alone inhibited the phosphorylation of 
IKB-α (Figure 2 A-B). In contrast, addition of 
lentinan to HBsAg-treated cells promoted the 
phosphorylation of IKB-α, indicating that lentinan 
induced functional recovery of THP-1 cells at 
least in part through activation of NF-kB 
signalling. This result was further confirmed by 
THP-1 cells treated with lentinan alone. 
Expression of IKB-α was negatively associated 
with the production of IL-1β, IL-12, and TNF-α. 
These results suggest that, at least in part, 
lentinan protected the function of 
monocytes/macrophages from the effect of 




Figure 2: Lentinan reduces IkB-α expression to 
activate NF-kB signalling in THP-1 cells. (A) IkB-α 
protein expression was measured by western blotting. 
(B) Densitometric analysis of (A). The relative 
expression of IkB-α was normalized to GADPH. Data 
are presented as mean and SD; *p < 0.05, **p < 0.01, 
and ***p < 0.001 compared with control; # vs. HBsAg; 
^ vs. lentinan)  
 
Lentinan restores the function of HBsAg-
treated THP-1 cells by activating the MAPK 
signalling pathway 
 
To investigate the role of the MAPK pathway in 
the process of immune-regulation induced by 
lentinan, activated THP-1 cells were treated with 
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HBsAg, lentinan and HBsAg+lentinan 
respectively, and then incubated with LPS. 
Reduced p-ERK expression and increased p-
JNK and p-p38 expression were observed in the 
THP-1 cells that simultaneously incubated with 
500 μg/ml lentinan and 25 μg/ml HBsAg when 
compared with cells treated with HBsAg alone 
(Figure 3A-B). The presence of HBsAg facilitated 
phospho-ERK expression, but dramatically 
repressed the phosphorylation of JNK and p38. 
Consistently, the addition of lentinan resulted in 
reduced expression of p-ERK, p-JNK, and p-p38 
in the cells treated with HBsAg. 
Figure 3: Lentinan regulates the MAPK signalling 
pathway to relieve HBsAg-induced functional 
impairment in THP-1 cells. (A) Phospho (p)-ERK, total 
(T)-ERK, p-JNK, T-JNK, p-p38, and T-p38 protein 
levels were assessed by western blot. (B) 
Densitometric analysis of the western blots. 
Expression levels were normalized to GADPH. Data 
are presented as mean and SD; *p < 0.05, **p < 0.01, 
and ***p < 0.001 compared with control; # vs. HBsAg; 




Lentinan is an immune response modifier and an 
anti-cancer drug for stomach cancer [12,14]. 
Lentinan enhances host immunity by activating 
monocytes/macrophages and neutrophil 
antimicrobial functions [13,15]. The β-glucan 
structure of lentinan can directly bind to dectin-14 
that is expressed on the surface of neutrophils, 
macrophages, and natural killer cells [16]. As a 
polysaccharide, lentinan also has various effects 
on inflammatory signalling pathways, such as 
NF-kB, MAPK, and the inflammasome [17]. 
Although lentinan promotes the activity of 
macrophages and CTLs, it may also inhibit the 
progress of inflammation in vivo by blocking pro-
inflammatory cytokines, such as IL-1β and IL-18 
[17].  
 
Several studies have examined the immune-
modulating effects of lentinan in cancer 
treatments. Tumour patients who received 
lentinan enhanced survival rates [14,18]. 
Administration of lentinan promoted the 
generation of CTLs, as well as the complement 
response that helped the CTLs recognize tumour 
cells. Moreover, macrophage cytotoxic activities 
and TNF production were enhanced after 
administration of lentinan [19]. 
 
Cancer patients show potent immuno-
suppression in tumour microenvironments, as 
well as in the circulatory system [20]. Myeloid-
derived suppressor cells (MDSCs) induce failure 
of host anti-tumour immune responses and 
repress the functions of CTLs, resulting in tumour 
survival and expansion [21]. Indeed, some 
MDSCs share the phenotype of a monocyte 
subset; thus, lentinan may function on these cells 
to promote host anti-tumour responses. Patients 
chronically infected with HBV have insufficient 
antiviral immune responses. These deficits 
presented as the impairment of myeloid subsets, 
indicating that the repression of the host innate 
immune arm may be a leading cause of 
systematic immuno-suppression [22]. These data 
suggested that lentinan might have a role in 
chronic HBV treatment.  
 
In this study, addition of lentinan recovered the 
production of IL-1β, IL-12, and TNF-α in a dose-
dependent manner by THP-1 cells that exposed 
to HBsAg. The underlying mechanisms were 
associated with activation of NF-kB and MAPK 
signal pathways. Upon LPS stimulation, THP-1 
cells treated with HBsAg alone showed 
decreased IkB-α expression; co-incubation with 
lentinan significantly promoted IkB-α 
degradation. Thus, lentinan affected NF-kB 
signalling to recover cytokine production. Since 
the MAPK signal pathway was indicated in both 
HBsAg- and lentinan-induced inflammatory 
responses, the protein levels of p-ERK, p-JNK, 
and p-p38 protein levels were further measured. 
THP-1 cells incubated with lentinan and HBsAg 
showed decreased expression of IkB-α and p-
ERK and increased expression of p-JNK and p-
p38. Notably, the addition of 500 μg/ml lentinan 
alone inhibited the production of these pro-
inflammatory cytokines, but significantly reduced 
the expression of IkB-α and repressed process of 
ERK, JNK, and p38 phosphorylation following 
LPS stimulation. 
 
In addition to activating the NF-kB and MAPK 
signalling pathways, lentinan alters 
inflammasome activation and cytokine 
maturation [13]. It triggers expression of pro-
inflammatory cytokines via the NLRP3 
inflammasome and selectively inhibits cytokine 
secretion in response to AIM2 inflammasome 
activation in a colitis model [17]. These findings 
may explain why lentinan alone decreased 
cytokine production on further LPS stimulation.  
The conventional treatments for HBV infection, 
including pegylated interferon-α and nucleotide 
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analogues, halt the progression of active liver 
disease, but do not clear HBV infections [23]. 
These treatments are costly and generally need 
long-term administration, though they are 
effective at reducing disease exacerbation. 
Compared to recombinant interferon-α or 
nucleotide analogues, lentinan is accessible and 




The findings of this study demonstrate that 
lentinan activates NF-kB and MAPK signalling 
pathways in vitro to enhance the function of 
monocytes/macrophages in the presence of 
HBsAg. These results support the potentials of 
lentinan in HBV treatment and thus, warrant the 
need for further studies of its effects in an in vivo 
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